Advertisement

Journal of Nephrology

, Volume 30, Issue 4, pp 521–529 | Cite as

Is incremental hemodialysis ready to return on the scene? From empiricism to kinetic modelling

  • Carlo Basile
  • Francesco Gaetano Casino
  • Kamyar Kalantar-Zadeh
Review

Abstract

Most people who make the transition to maintenance dialysis therapy are treated with a fixed dose thrice-weekly hemodialysis regimen without considering their residual kidney function (RKF). The RKF provides effective and naturally continuous clearance of both small and middle molecules, plays a major role in metabolic homeostasis, nutritional status, and cardiovascular health, and aids in fluid management. The RKF is associated with better patient survival and greater health-related quality of life, although these effects may be confounded by patient comorbidities. Preservation of the RKF requires a careful approach, including regular monitoring, avoidance of nephrotoxins, gentle control of blood pressure to avoid intradialytic hypotension, and an individualized dialysis prescription including the consideration of incremental hemodialysis. There is currently no standardized method for applying incremental hemodialysis in practice. Infrequent (once- to twice-weekly) hemodialysis regimens are often used arbitrarily, without knowing which patients would benefit the most from them or how to escalate the dialysis dose as RKF declines over time. The recently heightened interest in incremental hemodialysis has been hindered by the current limitations of the urea kinetic models (UKM) which tend to overestimate the dialysis dose required in the presence of substantial RKF. This is due to an erroneous extrapolation of the equivalence between renal urea clearance (Kru) and dialyser urea clearance (Kd), correctly assumed by the UKM, to the clinical domain. In this context, each ml/min of Kd clears the urea from the blood just as 1 ml/min of Kru does. By no means should such kinetic equivalence imply that 1 ml/min of Kd is clinically equivalent to 1 ml/min of urea clearance provided by the native kidneys. A recent paper by Casino and Basile suggested a variable target model (VTM) as opposed to the fixed model, because the VTM gives more clinical weight to the RKF and allows less frequent hemodialysis treatments at lower RKF. The potentially important clinical and financial implications of incremental hemodialysis render it highly promising and warrant randomized controlled trials.

Keywords

End-stage renal disease Incremental hemodialysis Initiation of dialysis Residual renal function Twice-weekly hemodialysis Urea kinetic modelling 

Notes

Compliance with ethical standards

Funding

No funding agency granted the present study.

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

For this type of study formal consent is not required.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Saran R, Li Y, Robinson B et al (2016) US renal data system 2015 annual data report: epidemiology of kidney disease in he US. Am J Kidney Dis 67(Suppl 1):S1–S305Google Scholar
  2. 2.
    Toth-Manikowski SM, Shafi T (2016) Hemodialysis prescription for incident patients: twice seems nice, bt is it incremental? Am J Kidney Dis 68:180–183CrossRefPubMedGoogle Scholar
  3. 3.
    Lowrie EG, Laird NM, Parker TF et al (1981) Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 305:1176–1181CrossRefPubMedGoogle Scholar
  4. 4.
    Eknoyan G, Beck GJ, Cheung AK et al (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010–2019CrossRefPubMedGoogle Scholar
  5. 5.
    Blagg CR (2011) The 50th anniversary of long-term hemodialysis: University of Washington Hospital, March 9th, 1960. J Nephrol 24(Suppl 17):S84–S88CrossRefPubMedGoogle Scholar
  6. 6.
    (2001)NKF-K/DOQI clinical practice guidelines for hemodialysis adequacy:update 2000. Am J Kidney Dis 37(Suppl 1):S7–S64Google Scholar
  7. 7.
    Chertow GM, Levin NW, Beck GJ et al (2010) In-center hemodialysis six times per week versus three times per week. N Engl J Med 363:2287–2300CrossRefPubMedGoogle Scholar
  8. 8.
    Couchoud C, Kooman J, Finne P et al (2009) From registry data collection to international comparisons: examples of haemodialysis duration and frequency. Nephrol Dial Transplant 24:217–224CrossRefPubMedGoogle Scholar
  9. 9.
    Rhee CM, Unruh M, Chen J et al (2013) Infrequent dialysis: a new paradigm for hemodialysis initiation. Semin Dial 26:720–727CrossRefPubMedGoogle Scholar
  10. 10.
    Zhang M, Wang M, Li H et al (2014) Association of initial twice-weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients. Am J Nephrol 40:140–150CrossRefPubMedGoogle Scholar
  11. 11.
    Daugirdas JT, Green T, Rocco MV et al (2013) Effect of frequent hemodialysis on residual kidney function. Kidney Int 83:949–958CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Golper TA, Mehrotra R (2015) The intact nephron hypothesis in reverse: an argument to support incremental dialysis. Nephrol Dial Transplant 30:1602–1604CrossRefPubMedGoogle Scholar
  13. 13.
    Sandrini M, Vizzardi V, Valerio F et al (2016) Incremental peritoneal dialysis: a 10 year single-centre experience. J Nephrol 29:871–879CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hanson JA, Hulbert-Shearon TE, Ojo AO et al (1999) Prescription of twice-weekly hemodialysis in the USA. Am J Nephrol 19:625–633CrossRefPubMedGoogle Scholar
  15. 15.
    Lin YF, Huang JW, Wu MS et al (2009) Comparison of residual renal function in patients undergoing twice-weekly versus three-times-weekly haemodialysis. Nephrology (Carlton) 14:59–64CrossRefGoogle Scholar
  16. 16.
    Supasyndh O, Satirapoj B, Seenamngoen S et al (2009) Nutritional status of twice and thrice-weekly hemodialysis patients with weekly Kt/V > 3.6. J Med Assoc Thai 92:624–631PubMedGoogle Scholar
  17. 17.
    Vilar E, Wellsted D, Chandna SM et al (2009) Residual renal function improves outcome in incremental hemodialysis despite reduced dialysis dose. Nephrol Dial Transplant 24:2502–2510CrossRefPubMedGoogle Scholar
  18. 18.
    Stankuviene A, Ziginskiené E, Kuzminskis V et al (2010) Impact of hemodialysis dose and frequency on survival of patients on chronic hemodialysis in Lithuania during 1998–2005. Medicina (Kaunas) 46: 516–521Google Scholar
  19. 19.
    Lin X, Yan Y, Ni Z et al (2012) Clinical outcome of twice-weekly hemodialysis in Shangai. Blood Purif 33:66–72CrossRefPubMedGoogle Scholar
  20. 20.
    Elamin S, Abu-Aisha H (2012) Reaching target hemoglobin level and having a functioning arteriovenous fistula significantly improve one year survival in twice weekly hemodialysis. Arab J Nephrol Transplant 5:81–86PubMedGoogle Scholar
  21. 21.
    Fernandez-Lucas M, Teruel-Briones JL, Gomis-Couto A et al (2012) Maintaining residual renal function in patients on haemodialysis: 5-year experience uing a progressively increasing dialysis regimen. Nefrologia 32:767–776PubMedGoogle Scholar
  22. 22.
    Caria S, Cupisti A, Sau G et al (2014) The incremental treatment of ESRD: a low-protein diet combined with weekly hemodialysis may be beneficial for selected patients. BMC Nephrol 15:172CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Park JI, Park JT, Kim JL et al (2017) Comparison of outcoms between the incremental and thrice-weekly initiation of hemodialysis: a propensity-matched study of a prospective cohort in Korea. Nephrol Dial Transplant 32:355–362PubMedGoogle Scholar
  24. 24.
    Obi Y, Streja E, Rhee CM et al (2016) Incremental hemodialysis, residual kidney function, and mortality risk in incident dialysis patients: a cohort study. Am J Kidney Dis 68:256–265CrossRefPubMedGoogle Scholar
  25. 25.
    Obi Y, Rhee CM, Mathew AT et al (2016) Residual kidney function decline and mortality in incident hemodialysis patients. J Am Soc Nephrol 27:3758–3768CrossRefPubMedGoogle Scholar
  26. 26.
    Mathew AT, Obi Y, Rhee CM et al (2016) Treatment frequency and mortality among incident hemodialysis patients in the US comparing incremental standard and more frequent dialysis. Kidney Int 90:1071–1079CrossRefPubMedGoogle Scholar
  27. 27.
    Smith HW, Goldring W, Chasis H (1938) The measurement of the tubular excretory mass, effective blood flow and filtration rate in the normal human kidney. J Clin Invest 17:263–278CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Davenport A (2016) Measuring residual renal function in dialysis patients: can we dispense with 24-hour urine collections? Kidney int 89:978–980CrossRefPubMedGoogle Scholar
  29. 29.
    van Olden RW, van Acker BA, Koomen GC et al (1995) Time course of inulin and creatinine clearance in the interval between two haemodialysis treatments. Nephrol Dial Transplant 10:2274–2280CrossRefPubMedGoogle Scholar
  30. 30.
    Wong J, Vilar E, Davenport A et al (2015) Incremental haemodialysis. Nephrol Dial Transplant 30:1639–1648CrossRefPubMedGoogle Scholar
  31. 31.
    Bhavsar N, Appel L, Kusek J et al (2011) Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis 58:886–893CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Shafi T, Michels WM, Levey AS et al (2016) Estimating residual kidney function in dialysis patients without urine collection. Kidney Int 89:1099–1110CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Wong J, Sridharan S, Berdeprado J et al (2016) Predicting residual kidney function in hemodialysis patients using serum β-trace protein and β2-microglobulin. Kidney Int 89:1090–1098CrossRefPubMedGoogle Scholar
  34. 34.
    Kalantar-Zadeh K, Unruh M, Zager PG et al (2014) Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy. Am J Kidney Dis 64:181–186CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Kalantar-Zadeh K, Casino FG (2014) Let us give twice-weekly hemodialysis a chance: revisiting the taboo. Nephrol Dial Transplant 29:1618–1620CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Shafi T, Jaar BG, Plantinga LC et al (2010) Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) study. Am J Kidney Dis 56:348–358CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    van der Wal WM, Noordzij M, Dekker FW et al (2011) Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant 26:2978–2983CrossRefPubMedGoogle Scholar
  38. 38.
    Marquez IO, Tambra S, Luo FJ et al (2011) Contribution of residual renal function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol 6:290–296CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Menon MK, Naimark DM, Bargman JM et al (2001) Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 16:2207–2213CrossRefPubMedGoogle Scholar
  40. 40.
    Wang AY, Wang M, Woo J et al (2002) A novel association between residual renal function and left ventricular hyperthrophy in peritoneal dialysis patients. Kidney Int 62:639–647CrossRefPubMedGoogle Scholar
  41. 41.
    Suri RS, Larive B, Sherer S et al (2013) Risk of vascular access complications with frequent hemodialysis. J Am Soc Nephrol 24:498–505CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Liu S, Diao Z, Zhang D et al (2014) Preservation of residual renal function by not removing water in new hemodialysis patients: a randomized, controlled study. Int Urol Nephrol 46:83–90CrossRefPubMedGoogle Scholar
  43. 43.
    Libetta C, Nissani P, Dal Canton A (2016) Progressive hemodialysis: is it the future? Semin Dial 29:179–183CrossRefPubMedGoogle Scholar
  44. 44.
    Foley RN, Gilbertson DT, Murray T et al (2011) Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 365:1099–1107CrossRefPubMedGoogle Scholar
  45. 45.
    Zhang H, Schaubel DE, Kalbfleisch JD et al (2012) Dialysis outcomes and analysis of practice patterns suggests the dialysis schedule affects day-of-week mortality. Kidney Int 81:1108–1115CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Krishnasamy R, Badve SV, Hawley CM et al (2013) Daily variation in death in patients treated by long-term dialysis: comparison of in-center hemodialysis to peritoneal and home hemodialysis. Am J Kidney Dis 61:96–103CrossRefPubMedGoogle Scholar
  47. 47.
    Rhee CM, Kalantar-Zadeh K (2015) Implications of the long interdialytic gap: a problem of excess accumulation vs. excess removal? Kidney Int 88:442–444CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Burton JO, Jefferies HJ, Selby NM et al (2009) Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 4:914–920CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Shoij T, Tsubakihara Y, Fujii M et al (2004) Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 66:1212–1220CrossRefGoogle Scholar
  50. 50.
    Flythe JE, Kimmel SE, Brunelli SM (2011) Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 79:250–257CrossRefPubMedGoogle Scholar
  51. 51.
    Casino FG, Lopez T (1996) The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant 11:1574–1581CrossRefPubMedGoogle Scholar
  52. 52.
    Shemin D, Bostom AG, Laliberty P et al (2001) Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38:85–90CrossRefPubMedGoogle Scholar
  53. 53.
    (2015) NKF-K/DOQI clinical practice guidelines for hemodialysis adequacy: 2015 update. Am J Kidney Dis 66:884–930Google Scholar
  54. 54.
    European Best Practice Guidelines Expert Group on Haemodialysis (2002) II.3 Haemodialysis dose and residual renal function (Kr). Nephrol Dial Transplant 17(Suppl 7):S24Google Scholar
  55. 55.
    Sargent JA, Gotch FA (1980) Mathematic modeling of dialysis therapy. Kidney Int Suppl 10:S2–S10PubMedGoogle Scholar
  56. 56.
    Vilar E, Farrington K (2011) Emerging importance of residual renal function in end-stage renal failure. Semin Dial 24:487–494CrossRefPubMedGoogle Scholar
  57. 57.
    Fry AC, Singh DK, Chandna SM et al (2007) Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif 25:295–302CrossRefPubMedGoogle Scholar
  58. 58.
    Penne EL, van der Weerd NC, Blankestijn PJ et al (2010) Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients. Clin J Am Soc Nephrol 5:80–86CrossRefPubMedGoogle Scholar
  59. 59.
    Oates T, Pinney JH, Davenport A (2011) Haemodiafiltration versus high-flux haemodialysis: effects on phosphate control and erythropoietin response. Am J Nephrol 33:70–75CrossRefPubMedGoogle Scholar
  60. 60.
    Vilar E, Boltiador C, Viljoen A et al (2014) Removal and rebound kinetics of cystatin C in high-flux hemodialysis and hemodiafiltration. Clin J Am Soc Nephrol 9:1240–1247CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Bammens B, Evenepoel P, Verbeke K et al (2003) Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 64:2238–2243CrossRefPubMedGoogle Scholar
  62. 62.
    Masereeuw R, Mutsaers HA, Toyohara T et al (2014) The kidney and uremic toxin removal: glomerulus or tubule? Semin Nephrol 34:191–208CrossRefPubMedGoogle Scholar
  63. 63.
    Gotch FA, Sargent JA (1985) A mechanistic analysis of the National Cooperative Dialysis study (NCDS). Kidney Int 28:526–534CrossRefPubMedGoogle Scholar
  64. 64.
    Basile C, Lomonte C (2012) Kt/V urea does not tell it all. Nephrol Dial Transplant 27:1284–1287CrossRefPubMedGoogle Scholar
  65. 65.
    Penne EL, van der Weerd NC, Grooteman MP et al (2011) Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol 6:281–289CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Wang AY, Sea MM, Ip R et al (2001) Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 12:2450–2457PubMedGoogle Scholar
  67. 67.
    Wang AY, Woo I, Wang M et al (2005) Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 20:396–403CrossRefPubMedGoogle Scholar
  68. 68.
    Chandna SM, Farrington K (2004) Residual renal function: considerations on its importance and preservation in dialysis patients. Semin Dial 17:196–2001CrossRefPubMedGoogle Scholar
  69. 69.
    Gotch FA (1998) The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 13(Suppl 6):S10–S14CrossRefGoogle Scholar
  70. 70.
    Casino FG, Basile C (2017) The variable target model: a paradigm shift in the incremental haemo dialysis prescription. Nephrol Dial Transplant 32:182–190CrossRefPubMedGoogle Scholar
  71. 71.
    Teruel-Briones JL, Fernández-Lucas M, Rivera-Gorrin M et al (2013) Progression of residual renal function with an increase in dialysis: haemodialysis versus peritoneal dialysis. Nefrologia 33:640–649PubMedGoogle Scholar
  72. 72.
    Mathew AT, Fishbane S, Obi Y et al (2016) Preservation of residual kidney function in hemodialysis patients: reviving an old concept. Kidney Int 90:262–271CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Nephrology 2017

Authors and Affiliations

  1. 1.Clinical Research Branch, Division of NephrologyMiulli General HospitalAcquaviva delle FontiItaly
  2. 2.Dialysis Centre SM2PotenzaItaly
  3. 3.Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and HypertensionUniversity of California Irvine, School of MedicineOrangeUSA
  4. 4.Fielding School of Public Health at UCLALos AngelesUSA
  5. 5.Los Angeles Biomedical Research Institute at Harbor-UCLATorranceUSA

Personalised recommendations